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Richard J. Powell, MD,a Christopher Alessi, MD,a Brian Nolan, MD,b Eva Rzucidlo, MD,a
Mark Fillinger, MD,a Daniel Walsh, MD,a Mark Wyers, MD,b Robert Zwolak, MD, PhD,b
and Jack L. Cronenwett, MD,a Lebanon, NH; and White River Junction, Vt
Background: Embolic protection devices (EPDs) consisting of an internal carotid artery (ICA) filter or balloon occlusion
are typically used during carotid artery stenting (CAS). This study compares the technical difficulties encountered using
these two types of EPD.
Methods: A retrospective review was conducted of patients undergoing CAS using a balloon occlusion EPD (balloon
group: PercuSurge GuardWire) or filter EPD (filter group: Accunet, AngioGuard, or FilterWire). Complications were
defined as minor stroke, National Institutes of Health (NIH) stroke scale <3; major stroke, NIH stroke scale >3;
transient ischemic attack (TIA), reversible focal neurologic impairment; technical, reversible neurologic compromise
during EPD deployment, inability to cross lesion, ICA spasm requiring treatment, EPD-related factors that prolonged
CAS.
Results:CAS (n 141) was performed in 133 patients (82%men) with a mean age of 72 of years. Comorbidities included
diabetes, 35%; coronary artery disease, 75%; hypertension, 82%; and renal insufficiency, 15%. Indication was previous
cerebrovascular accident in 10%, TIA in 29%, and asymptomatic >80% stenosis in 61%. Primary lesions were treated in
83% vs restenosis in 17%. The 30-day event rate was 1.4%major stroke, 2.1%minor stoke, 1.4%myocardial infarction, and
0.7% death. The overall combined 30-day stroke, death, and myocardial infarction rate was 5.6%. The 30-day stroke and
death rate was 4.0% in the balloon group (n  99) and 4.6% in the filter group (n  42, P  .51). EPD-related technical
difficulties occurred in 15% of the balloon group and 31% of the filter group (P < .05). Technical difficulties included a
10% incidence of reversible neurologic compromise during balloon deployment compared with 0% in the filter group
(P  .002) and 12% incidence of inability to cross the lesion before predilation in the filter group compared with 0% in
the balloon group (P  .001).
Conclusions:During CAS, both balloon occlusion and filter devices provide acceptable results and appear complimentary.
Filters can be used preferentially to avoid a 10% incidence of reversible neurologic compromise associated with balloon
occlusion, except in critically narrowed or tortuous lesions when balloon occlusion may be preferred because of a 12%
need for unprotected predilatation with filters. ( J Vasc Surg 2006;44:56-61.)Carotid artery stenting (CAS) has become an accepted
alternative to carotid endarterectomy (CEA) for the treat-
ment of obstructive extracranial carotid artery occlusive
disease in selected high-risk patients.1 A major concern is
the risk of atheroembolic material released from the carotid
plaque during CAS.2 Initial use of CAS was hindered by an
increased incidence of neurologic complications and stroke
compared with CEA.3 In several series, which were largely
performed without the use of any cerebral protection,
stroke rates were 10%.4,5
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56The development and subsequent introduction of
embolic protection devices (EPDs) has resulted in a
decreased rate of stroke after CAS.1,6,7 Thus, the use of
EPDs during CAS is now routine. At present, the three
different classes of EPDs are (1) balloon occlusion EPDs
that require occlusion of the ICA during CAS, (2) filter
EPDs that rely on a filter in the distal internal carotid
artery (ICA) to capture atheroembolic particles released
during CAS while permitting antegrade cerebral perfu-
sion, and (3) flow reversal/cessation devices that use
common carotid balloon occlusion to promote retro-
grade or no flow in the ICA during CAS.8-10 Retrograde
and flow cessation techniques are promising but have not
yet gained widespread clinical use compared with the
balloon occlusion and filter EPDs as they remain inves-
tigational at this time.8-10
Although many types of EPDs exist, all with theoretical
advantages and disadvantages, few comparative studies
have confirmed or identified any unique advantages or roles
that specific EPDs may have in CAS. Because of the dra-
matic differences in EPD design, it is likely that there are
anatomic situations in which individual EPDsmay be better
suited to prevent stroke during CAS. The purpose of this
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encountered with balloon occlusion and filter EPDs.
METHODS
The records of all patients treated with CAS for extracra-
nial carotid bifurcation occlusive disease from the first patient
treated in December 2002 through September 2005 were
reviewed. Excluded were patients who had stent-graft place-
ment for trauma (n 3), stents placed at the time of CEA for
distal flap (n  4), combined coronary artery bypass grafting
and CAS (n 1), and patients in whom CAS was performed
before the availability of EPDs (n  4). The data had been
prospectively entered into a database. This review was ap-
proved by the institutional review board.
For purposes of this review, high-risk patients were
classified as having either anatomic high risk or medical
high risk. Anatomic high risk included 44 patients with
previous carotid surgery, neck dissection, radiation therapy
to the neck, lesions extending above the C2 vertebral body,
presence of a neck stoma, or contralateral cranial nerve
injury. Medical high risk (n 75) included cardiac comor-
bidity, defined as myocardial infarction (MI) or congestive
heart failure 3 months, or unreconstructed severe coro-
nary artery disease, and pulmonary comorbidity that re-
quired home oxygen. Initially, only high-risk patients were
offered CAS, but with increased experience, this procedure
was offered to 22 normal-risk patients.
Patients received either 1 week of clopidogrel (75 mg
daily) before the procedure or a single 300-mg loading
dose of clopidogrel the morning of the procedure. In
addition, patients were maintained on oral aspirin indefi-
nitely and clopidogrel (Bristol-Myers Squibb, New York,
NY) for a least 1 month after the procedure. Our CAS
technique has been previously described in detail.6 Carotid
duplex scanning was performed at 1 day, 1 month, 6
months, and yearly thereafter.
An independent neurologist examined 40 patients who
were enrolled in clinical trials. The 101 patients not en-
rolled in a clinical trial underwent a neurologic examination
by the general surgery chief resident or vascular fellow plus
the surgical attending on postoperative day 1 and at each
clinic visit. An independent neurologic assessment was
conducted in 75% patients treated with filters as part of a
clinical trial, but only 25% of balloon-treated patients un-
derwent independent neurologic assessment.
Patients with any new neurologic deficit were scored
using the National Institutes of Health (NIH) stroke
scale.6 A major stroke was defined as a new neurologic
event that lasted24 hours and had an increase in the NIH
stroke scale of 3. A minor stroke was defined as a new
neurologic event that lasted 24 hours and was associated
with an increase in the NIH stroke scale of3. A transient
ischemic attack (TIA) was defined as a new neurologic
deficit that lasted 24 hours.
MI was defined as an elevated troponin T level 0.03
ng/mL or an abnormal postoperative electrocardiogram
consistent with new MI.Blood pressure control complications were defined as
the need to use intravenous vasoactive medication to lower
or raise the blood pressure in a monitored setting after
CAS. The blood pressure goals for each patient were differ-
ent and determined by previous blood pressure, presence of
intracranial occlusive disease, and severity of the stenosis
treated.
Technical difficulty was defined as neurologic compro-
mise during EPD deployment, inability to cross the ICA
lesion with the EPD without predilation, ICA spasm re-
quiring pharmacologic treatment, and any EPD-related
event outside of the typical CAS procedure that prolonged
the CAS procedure. A transient neurologic deficit that
developed during inflation of the embolization protection
balloon or with deployment of the filter that completely
resolved with deflation of the balloon or filter capture was
not considered to be a TIA. This was considered a technical
difficulty with use of the EPD and was defined as reversible
Fig 1. The 99 patients in the balloon group received a GuardWire
embolic protection device.
Fig 2. Patients in the filter group received the Accunet, Angio-
Guard, or FilterWire filter embolic protection devices.neurologic compromise.
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cross the lesion only after unprotected predilation was
considered an EPD-related technical difficulty and was
recorded for both types of EPD. Spasm was defined as ICA
narrowing in a previously normal portion of the carotid
artery above the stent.
The initial 90 patients treated in the study underwent
CAS using the GuardWire PercuSurge EPD (Medtronic,
Santa Rosa, Calif). Subsequent patients were enrolled in
clinical trials, either CREST (Carotid Revascularization End-
arterectomy vs. Stent Trial) (NIH/Guidant) or ADVANCE
(Action in Diabetes and Vascular Disease: Preterax and
Diamicron MR Controlled Evaluation) (Cordis), and re-
ceived the corresponding filter device. Upon Food and Drug
Administration (FDA) approval of the Guidant Accunet Fil-
ter, surgeon preference also factored into which EPD device
was chosen. Patients receiving a GuardWire EPD (Fig 1)
during CAS (balloon group) were compared with patients
receiving filter EPDs (filter group), which included Accunet
(Guidant, Indianapolis, Ind), AngioGuard (Cordis, Warren,
NJ), and FilterWire (Boston Scientific, Natick, Mass) (Fig 2).
The variables compared between the two groups included
incidence of stroke, death, myocardial infarction, and techni-
cal difficulties experienced with the use of the two types of
EPD.
Data are presented as the mean standard error of the
mean. Statistical analysis was performed using analysis of
variance with post hoc t test or 2, where appropriate, using
Table I. Patient demographics
Filter
(n  42)
Balloon
(n  99) P
Mean age (years) 71 73 .27
Male 74% 89% .02
Diabetic 29% 35% .54
CAD 24% 25% .95
Tobacco* 73% 81% .54
ACE 62% 67% .63
Statin 67% 74% .83
HTN 80% 79% .34
CAD, Coronary artery disease; ACE, angiotensin converting enzyme inhib-
itor; HTN, hypertension.
*Present tobacco use or within past 2 years.
Table II. Lesion presentation of patients in the study
groups
Filter
(n  42) (%)
Balloon
(n  99) (%) P
Asymptomatic 64 60 .45
TIA 29 29
CVA 7 11
Primary lesion 74 89 .05
Restenosis 26 11
Anatomic risk 38 23 .21
Medical risk 38 49 .31
TIA, Transient ischemic attack; CVA, cerebrovascular accident.StatView Software (SAS Institute Inc, Carey, NC).RESULTS
During the described time period, 141CAS procedures
were performed in 133 patients at Dartmouth Hitchcock
Medical Center and theWhite River Junction VAHospital.
Patients were a mean age of 72 years (82% men). Comor-
bidities included diabetes in 35%, coronary artery disease in
75%, hypertension in 82%, and renal insufficiency in 15%.
Indication was previous cerebrovascular accident in 10%,
TIA in 29%, and asymptomatic 80% stenosis in 61%.
Primary lesions were treated in 83% vs restenosis in 17%.
Balloon occlusion protection was used in 99 proce-
dures and filter protection in 42 procedures. The patient
characteristics for the balloon and filter groups are summa-
rized in Table I. No significant differences were noted
between the two groups with the exception of an increased
number of men in the balloon group. As shown in Table II,
there was no difference in symptoms at presentation be-
tween the two groups. However, more patients in the filter
group were treated for restenosis compared with the bal-
loon group (P  .05).
For the entire cohort, the 30-day event rate was 1.4%
major stroke, 2.1% minor stoke, 1.4% MI, and 0.7% death.
No intracranial embolization occurred during or immedi-
ately after CAS. All strokes occurred between 2 and 12
hours after the procedure. There were no instances of
embolization to the proximal M1-2, A1-2 segments as
determined by arteriography or computed tomography
arteriography. All cases of stroke appeared to be a result of
distal microembolization. The overall combined 30-day
Table III. Thirty-day perioperative outcome
Filter
(n  42) (%)
Balloon
(n  99) (%) P
Major stroke 2.3 1.0 .51
Minor stroke 2.3 2.0 .82
TIA 0 1.0 .73
MI 0 2.0 .56
Reperfusion 0 2.0 .56
BP control 9.5 5 .63
Seizure 2.3 2.0 .82
TIA, Transient ischemic attack; MI, myocardial infarction; BP, blood pres-
sure control requiring pressors.
Table IV. Technical complications
Filter
(n  42) (%)
Balloon
(n  99) (%) P
Neurologic comp 0 10 .002
Unable to cross lesion 12 0 .001
Filter clogged 5 0 .07
ICA spasm 12 2 .002
Malpositioned stent 0 2 .56
Other* 7 1 .16
ICA, Internal carotid artery.
*3 cases of delayed retrieval of filter and one case of balloon wire kinkingstroke, death, and MI rate was 5.6%.
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dence of minor stroke, major stroke, MI, or death (Table
III), EPD-related technical difficulties occurred in 15% of
the balloon group and 31% of the filter group (P  .05).
These difficulties are detailed in Table IV. Technical diffi-
culties were EPD specific. No correlation was found be-
tween EPD-related technical difficulties and adverse neu-
rologic outcomes after CAS.
Transient neurologic compromise occurred in 10% of
the balloon group while the balloon was deployed but did
not occur in the filter group (P  .002). In eight of ten
cases, neurologic changes occurred within several minutes
after inflation of the PercuSurge, the other two occurred
during bradyarrhythmia after post-stent balloon dilation.
All patients presented with global symptoms. In most cases,
the procedure was completed by deflating the balloon and
then increasing the mean arterial pressure by 20 to 25 mm
Hg above baseline. After this maneuver, eight of the ten
patients tolerated reinflation of the balloon EPD and stent
placement was completed. Two patients who could not
tolerate balloon EPD were treated with a filter device (n 
1) or CEA (n  1). Multivariate analysis did not identify
any predictors of failure to tolerate balloon EPD deploy-
ment. This included the presence of contralateral ICA
stenosis or occlusion.
Inability to cross the lesion without unprotected predi-
lation occurred in 12% of filter group patients but in none
of the balloon group (P  .001). In 5% of the filter group,
the lesion could not be crossed despite unprotected predi-
lation. In these cases, the CAS procedure was completed
using balloon EPD. The balloon EPD crossed all lesions
attempted.
Spasm requiring pharmacologic treatment occurred
more frequently in the filter group (12%) than the balloon
group (2%, P  .002). In all cases, however, the spasm
resolved after removal of the EPD and intra-arterial infu-
sion of 100 g of nitroglycerin through the arterial sheath.
It had no apparent clinical consequence.
Filter clogging with no reflow through the ICA was
observed in two cases. This required aspiration of the filter
basket with an Export catheter (Medtronic). In addition,
100 g of nitroglycerin was given through the sheath. In
both cases, flow was restored across the filter after aspira-
tion of the filter, which allowed safe capture and removal of
the filter.
In two cases in the balloon group, the ICA lesion was
not initially completely covered, and a second stent was
required. This was partly because of the inability to obtain
angiographic visualization of the ICA while the balloon
EPD is deployed. Additional less frequent complications
included prolonged time to remove the filter in three cases
and kinking of the balloon EPD before balloon inflation in
one case. These had no clinical consequence.
DISCUSSION
Few studies at present compare differences between bal-
loon and filter EPDs. Zahn et al11 reviewed the outcomes of
the Carotid Angioplasty and Stent Registry. In this largeseries, 553 patients received filter EPDs and 176 received
balloon EPDs. The neurologic event rates between the two
groups did not differ; however, balloonEPDswere usedmore
frequently in patients with complex or critically narrow steno-
ses. This study did not compare technical difficulties encoun-
tered with these two types of EPDs.
The PercuSurge GuardWire balloon occlusion wire has
had widespread clinical use even though it does not have
FDA approval for use in CAS. It has been shown to reduce
myocardial ischemic events after angioplasty of coronary
saphenous vein grafts and has FDA approval for this indi-
cation.12 Henry et al13 reported a stroke rate of 4% in
patients undergoing CAS with this embolization protec-
tion device. These authors found that 5% of patients did not
tolerate ICA balloon occlusion.
The MAVERIC (Evaluation of the Medtronic AVE
Self-Expanding Carotid Stent System in the Treatment of
Carotid Stenosis) trial, an open label trial utilizing the
GuardWire balloon occlusion EPD and Exponent stent
(Medtronic), reported a combined cardiac and neurologic
event rate of 5.4% in high risk patients.14 Theoretical
advantages of this device include greater ease of crossing
critically stenotic or tortuous lesions because of the low
crossing profile. The compliant balloon is mounted on a
hollow 0.014-inch wire with a crossing profile of 3.0F
(0.036-inch). In addition to low profile, the balloon EPD is
more flexible and allows for increased trackability.
Theoretical disadvantages of this device include con-
cerns that patients with severe contralateral carotid disease
may not neurologically tolerate ICA occlusion. This device
is also more complex to deploy compared with filters. The
findings from the present study support many of these
contentions. The balloon EPD crossed all lesions at-
tempted without the need for unprotected predilation.
However, 10% of patients did not tolerate initial balloon
occlusion. In these cases, the procedure could usually be
completed by deflating the balloon, transiently raising the
mean systemic blood pressure, and then reinflating the
balloon. No patient-specific or anatomic-specific predictors
of balloon occlusion intolerance were identified; however,
contralateral intracranial anatomy was not routinely as-
sessed either before or during the CAS procedure.
Filter EPDs are generally thought to be simpler to use
and offer the anticipated advantage that neurologic com-
promise is less likely than during use of balloon EPDs. For
these reasons, at least seven different filter designs have
currently completed or are in clinical trials. At present, only
two filter systems are FDA-approved for CAS, the Accunet
and Emboshield (Abbott, Abbott Park, Ill), although ap-
proval of several additional filter systems is likely in the near
future.15
Numerous clinical trials of various filter EPDs have
been completed. These results, summarized elsewhere,
have shown a combined 30-day cardiovascular adverse
event rate of 6% to 12%.16 These filter EPDs generally have
larger crossing profiles than balloon EPDs, from 3.4F to
3.9F (0.045 to 0.050 inches). In addition, filter EPDs have
an abrupt change between the floppy distal wire and the
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potential drawbacks may decrease the ability for filter EPDs
to cross critically stenotic or tortuous carotid bifurcation
stenoses.
The results of the present study confirm many of the
theoretical advantages of the filter EPDs. All patients in
whom the filter EPD could be deployed tolerated this
without neurologic compromise. In 7% of patients, how-
ever, the lesion could not be crossed until unprotected
balloon dilation was performed with a 1.5-mm or 2-mm
balloon. In two additional patients, the lesion could not be
crossed despite predilation, and balloon occlusion was suc-
cessfully used in these cases to complete CAS.
In addition to the development of neurologic compro-
mise and the inability to cross critically tight stenoses, our
study identified less frequent technical issues that appeared
to be EPD specific. These included difficulties with accu-
rate stent placement when the balloon EPD was used
because of the inability to angiographically visualize the
distal extent of the lesion as a result of occluded ICA flow.
Placement of a stiff stent over the balloon EPD can alter the
geometry of the ICA bifurcation. This is difficult to reassess
with angiography because of ICA occlusion during balloon
inflation. This required placement of a second ICA stent on
two occasions in the present study. In one additional case,
the balloon EPD wire was kinked before balloon deploy-
ment. This necessitated removal of the EPD and placement
of a second EPD. Kinking of the balloon EPD after balloon
inflation, although not observed in our experience, would
be of much greater concern, since deflation of the balloon
could be more difficult.
Filter clogging with embolic debris is an uncommon
problem that occurred in two patients in the filter group
during the present study. It is mandatory to perform repeat
angiography after post-stent balloon dilation before filter
removal to identify this problem. In the present study,
aspiration of the ICA and filter restored flow through the
filter and allowed safe removal. In two cases, the long
floppy portion of the guidewire that extends beyond the
filter would have crossed coexistent intracranial disease if it
had been used. In these cases, the filter was removed and
the procedure was completed with the balloon EPD in
which there is a shorter amount of wire that extends beyond
the balloon.
Finally, removal of the Guidant filter EPD filter was
prolonged in three patients. Removal of the filter was
hampered by the inability of the capture catheter to cross
the stent. This occurred despite preshaping the catheter tip.
Capture of the filter required placing the patient’s head in
various positions to straighten the stent, external neck
compression, or advancing the arterial sheath into the
proximal stent.
Technical difficulties were common with both types of
EPD but were not correlated with adverse outcomes. The
absence of any significant difference, however, could be due
to the relatively small numbers of patients in our study.CONCLUSIONS
EPD-related technical difficulties were encountered,
and although they appeared to have no effect on clinical
outcome, vascular surgeons need to be prepared to handle
these as they arise during CAS. In addition, familiarity with
different types of EPDs may allow the surgeon to treat a
broader clinical spectrum of patients with CAS. We prefer
to use filter devices preferentially in most cases to avoid the
10% incidence of reversible neurologic compromise that
occurs with balloon occlusion. However, we prefer balloon
occlusion EPDs for critical stenoses that would be more
difficult to cross with currently available filter systems with-
out predilation. With such critical stenoses, it is less likely
that the patients would not tolerate ICA occlusion. Thus,
balloon and filter type EPDs have complimentary advan-
tages and disadvantages that allow selection according to
unique patient and lesion characteristics.
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